Study details
Enrolling now
A Phase 1 Trial to Evaluate Safety and Pharmacokinetics of ABBV-243 in Healthy Adults
AbbVie
NCT IDNCT07306754ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
66
Study length
about 1.5 years
Ages
18–60
Locations
1 site in IL
About this study
Researchers are testing the safety, tolerability, pharmacokinetics, and immunogenicity of a treatment called ABBV-243. Participants will receive either an intravenous (IV) dose or a subcutaneous (SC) dose of ABBV-243, or a placebo. The trial will last for 532 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take ABBV-243
- 2.Take Placebo
PhasePhase 1
Primary goalMaximum Observed Serum Concentration (Cmax) of ABBV-243
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low11%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Maximum Observed Serum Concentration (Cmax) of ABBV-243, Number of Participants with Adverse Events (AEs), Terminal Phase Elimination Half-Life (t1/2) of ABBV-243, Time to Cmax (Tmax) of ABBV-243